SCHEDULE 13G: Deep Track Capital Discloses 5.44% Passive Stake in Nurix Therapeutics

Deep Track Capital, along with its affiliates Deep Track Biotechnology Master Fund, Ltd. and David Kroin, has disclosed a passive beneficial ownership of 5.44% in Nurix Therapeutics, Inc.'s common stock.

Summary

• Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have jointly filed a Schedule 13G, indicating beneficial ownership in Nurix Therapeutics, Inc.
• The reporting persons collectively own 4,125,000 shares of Nurix Therapeutics' Common Stock.
• This ownership represents 5.44% of the outstanding Common Stock of Nurix Therapeutics, Inc.
• The calculation of the percentage is based on 75,886,817 Common Stock outstanding, as reported in Nurix Therapeutics' 10-K filing on January 28, 2025.
• The shares are held with shared voting power and shared dispositive power among the reporting persons.
• The acquisition of these securities was not for the purpose of changing or influencing the control of Nurix Therapeutics.

Sentiment

Score: 6

Explanation: The document is a standard beneficial ownership disclosure (Schedule 13G), which is generally neutral. The disclosure of a new 5%+ passive stake by an investment firm can be viewed as a positive signal of investor confidence, hence a slightly positive score.

Positives

• Increased institutional ownership by a specialized biotechnology fund (Deep Track Capital) may signal confidence in Nurix Therapeutics' long-term prospects.
• The filing indicates a passive investment, suggesting the investor is not seeking to influence or control the company's management or strategy.

Negatives

• NA

Risks

• NA

Future Outlook

NA

Industry Context

This filing indicates a significant passive investment by a specialized fund in the biotechnology sector, which is common for funds focusing on growth opportunities within specific industries. Such disclosures provide transparency regarding institutional holdings in publicly traded companies.

Stakeholder Impact

• Shareholders: The disclosure of a significant passive stake by an institutional investor may be viewed positively, potentially increasing investor confidence and liquidity in the stock.

Key Dates

Keywords

Nurix Therapeutics, Deep Track Capital, Deep Track Biotechnology Master Fund, David Kroin, Schedule 13G, Beneficial Ownership, Common Stock, Biotechnology, Investment, SEC Filing